Traws Pharma
Open
$1.42
Prev. Close
$1.42
High
$1.42
Low
$1.42
Market Snapshot
$10.39M
1.7
67.73
$226K
7
Traws Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. The company is headquartered in Newtown, Pennsylvania and currently employs 7 full-time employees. The company went IPO on 2013-07-25. The company integrates antiviral drug development, medical intelligence and regulatory strategy in the treatment of viral diseases. The Cadvancing novel investigational oral small-molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health: bird flu and seasonal influenza, and COVID-19/Long COVID. Its four clinical programs consist of Tivoxavir marboxil, Ratutrelvir (TRX0), Narazaciclib, and Rigosertib. Tivoxavir marboxil is a small-molecule cap-dependent endonuclease inhibitor. Ratutrelvir (TRX01) is an inhibitor of the main protease (also known as 3CL protease) of the SARS-CoV-2 virus. arazaciclib is its oral CDK4-plus inhibitor intended initially to treat breast cancers, endometrial and other cancers. Rigosertib is its second asset in oncology.
emptyResult
Traws Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. The company is headquartered in Newtown, Pennsylvania and currently employs 7 full-time employees. The company went IPO on 2013-07-25. The company integrates antiviral drug development, medical intelligence and regulatory strategy in the treatment of viral diseases. The Cadvancing novel investigational oral small-molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health: bird flu and seasonal influenza, and COVID-19/Long COVID. Its four clinical programs consist of Tivoxavir marboxil, Ratutrelvir (TRX0), Narazaciclib, and Rigosertib. Tivoxavir marboxil is a small-molecule cap-dependent endonuclease inhibitor. Ratutrelvir (TRX01) is an inhibitor of the main protease (also known as 3CL protease) of the SARS-CoV-2 virus. arazaciclib is its oral CDK4-plus inhibitor intended initially to treat breast cancers, endometrial and other cancers. Rigosertib is its second asset in oncology.
Recently from Cashu
Traws Pharma Reports Oversight in Recent Financial Disclosure
It seems there was an oversight, as the text that needs to be summarized has not been provided. Please share the specific content regarding Traws Pharma or any relevant information, and I will gladly…
Traws Pharma Expands Innovative Biopharmaceuticals to Address Unmet Medical Needs and Enhance Patient Outcomes
Traws Pharma Expands Product Line with Innovative Biopharmaceuticals Traws Pharma, a key player in the biopharmaceutical industry, announces the expansion of its product line, focusing on innovative t…
Traws Pharma Leverages AI to Enhance Efficiency in Pharmaceutical Communications
Traws Pharma Embraces AI for Enhanced Efficiency in Pharmaceutical Communications Traws Pharma stands at the forefront of innovation in the pharmaceutical industry, reflecting a broader trend towards…